All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, on 19 March 2018, during the lymphoma oral session 1 (OS1), abstract OS1-3 was presented, by Mónica Baile, from the Hospital Universitario de Salamanca/IBSAL, Hematology, Salamanca, Spain regarding the latest findings from the Phase II GELTAMO study.
This study assessed the safety and efficacy of lenalidomide’s addition to R-ESHAP regimen (LR-ESHAP) in diffuse large B-cell lymphoma (DLBCL) patients with relapsed or refractory disease after rituximab-containing therapy. The primary endpoints for this study included the overall response rate (ORR) after 3 cycles of LR-ESHAP. The secondary objectives were the complete response (CR), event free-survival (EFS) and overall survival (OS).
This study demonstrated the feasibility of LR-ESHAP, producing high response rates in refractory and relapsed DLBCL patients. Additionally, this regimen was safe enabling a high percentage of patients to receive autologous transplant. It was also found that refractory patients fared worse than patients with relapsed disease, highlighting the need of alternative treatment for patients with primary refractory disease.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox